Почетна › Рак на жолчните патишта › Калифорнија
Клинички испитувања за Рак на жолчните патишта во Калифорнија
20 студии за Рак на жолчните патишта бараат учесници на локации во Калифорнија.
Градови во Калифорнија
Официјален текст на студијата (англиски)
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- City of Hope - Duarte Cancer Center, Duarte
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06760819AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Research Site, Orange
- Research Site, Palo Alto
- Research Site, Santa Rosa
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT06219941A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
- City of Hope (Site 107), Duarte
- University of California at Irvine (Site 101), Orange
- UCLA Medical Center (Site 117), Santa Monica
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT07265674Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
- USC Norris Comprehensive Cancer Center, Los Angeles
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT05482893A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Research Site, Duarte
- Research Site, Los Angeles
- Research Site, Orange
- и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07221253A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- UCLA ( Site 0317), Los Angeles
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06428409Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Los Angeles
- Research Site, Santa Rosa
Се регрутираФаза 2
Возраст од 18 до 130 · Сите полови · Ажурирано 23.9.2026 · NCT05489211Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- City of Hope, Duarte
- START - Los Angeles, Los Angeles
- Cedars Sinai, Los Angeles
- и уште 1
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 10.9.2026 · NCT06293898AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Los Angeles
- Avenzo Therapeutics Recruiting Site, Los Angeles
Се регрутираФаза 1/2
Возраст од 18 до 75 · Сите полови · Ажурирано 4.9.2026 · NCT07038343A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Hoag Family Cancer Institute, Newport Beach
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 21.8.2026 · NCT06774963Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, Fullerton
- Research Site, La Jolla
- Research Site, Los Angeles
- и уште 3
Се регрутираФаза 3
Возраст од 18 до 99 · Сите полови · Ажурирано 19.8.2026 · NCT06467357A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Los Angeles Cancer Network, Los Angeles
- Pih Health Hematology Medical Oncology, Whittier
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 5.8.2026 · NCT06330064A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Precision NextGen Oncology & Research Center, Beverly Hills
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
- University of California Los Angeles Rheumatology, Westwood, Los Angeles
Се регрутираФаза 2
Возраст 8 и постари · Сите полови · Ажурирано 27.7.2026 · NCT05503797Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
- University of California, Davis Comprehensive Cancer Center, Sacramento
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 2.7.2026 · NCT06101277A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Cedars-Sinai Medical Center, Los Angeles
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 29.6.2026 · NCT07458347A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- The City of Hope National Medical Center, Duarte
- Hoag Memorial Hospital, Newport Beach
Се регрутираФаза 1
Возраст 16 и постари · Сите полови · Ажурирано 2.6.2026 · NCT07197554Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Beverly Hills Cancer Center, Beverly Hills
- UC San Diego Moores Cancer Center, La Jolla
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 2.4.2026 · NCT05733598Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Stern Center for Cancer Clinical Trials and Research, Orange
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 5.3.2026 · NCT04900818Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
- Cedars-Sinai Medical Center, Los Angeles
Се регрутира
Возраст од 18 до 99 · Сите полови · Ажурирано 20.2.2026 · NCT04907643A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- University of Southern California, Los Angeles
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 11.12.2025 · NCT06943521Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.